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A B S T R A C T
Rationale and objective: The colorectal cancer (CRC) burden is increasing in Central and South American
due to an ongoing transition towards higher levels of human development. We describe the burden of
CRC in the region and review the current status of disease control.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries, as well as cancer deaths from the WHO mortality database for 18 countries. We
estimated world population age-standardized incidence (ASR) and mortality (ASMR) rates per
100,000 person-years for 2003–2007 and the estimated annual percentage change for 1997–2008.
Results: The CRC rate in males was 1–2 times higher than that in females. In 2003–2007, the highest ASRs
were seen in Uruguayan, Brazilian and Argentinean males (25.2–34.2) and Uruguayan and Brazilian
females (21.5–24.7), while El Salvador had the lowest ASR in both sexes (males: 1.5, females: 1.3). ASMRs
were <10 for both sexes, except in Uruguay, Cuba and Argentina (10.0–17.7 and 11.3–12.0). CRC incidence
is increasing in Chilean males. Most countries have national screening guidelines. Uruguay and Argentina
have implemented national screening programs.
Conclusion: Geographic variation in CRC and sex gaps may be explained by differences in the prevalence
of obesity, physical inactivity, diet, smoking and alcohol consumption, early detection, and cancer
registration practices. Establishing optimal CRC screening programs is challenging due to lack of
healthcare access and coverage, funding, regional differences and inadequate infrastructure, and may not
be feasible. Given the current status of CRC in the region, data generated by population-based cancer
registries is crucial for cancer control planning.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Colorectal cancer (CRC) is one of the most common cancers in
the world. With nearly 1.4 million new cases and 700,000 cancer
deaths occurring globally in 2012, CRC is the third leading
diagnosis and the fourth most common cause of cancer-related
deaths in both sexes combined [1]. The distribution of CRC varies
extensively across the globe; the highest age-standardized
incidence and mortality rates are observed in more developed
regions of the world (29.2 and 11.7 per 100,000, respectively)$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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E-mail address: sierram@fellows.iarc.fr (M.S. Sierra).
http://dx.doi.org/10.1016/j.canep.2016.03.010
1877-7821/ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd
creativecommons.org/licenses/by-nc-nd/3.0/igo/).whereas substantially lower rates are seen in less developed
regions (11.7 and 6.6 per 100,000, respectively) [1].
In the United States and Canada, Australia, New Zealand, and
most European countries, the incidence and mortality of CRC have
been declining or stabilizing since the 1970s; this may be explained
by reduced exposure to risk factors, earlier detection and
prevention, and improved treatments [2–7]. However, in countries
that have transitioned towards higher levels of human develop-
ment – such as those in Central and South America and Eastern
Europe – the burden of CRC has increased remarkably [3–5,8–10].
Risk factors for CRC include obesity, a diet high in calories and
animal fat, physical inactivity, tobacco smoking and heavy alcohol
consumption; these factors are also related to economic advance-
ment or “Westernization” [2,11–13].
The Central and South American region has undergone a rapid
epidemiologic and demographic transition, and the cancer proﬁle
is now changing from infection-related cancers (i.e., cervix and
stomach) to those cancers typically diagnosed in countries with
the highest human development, such as CRC [8,11,12]. GLOBOCAN
estimates of 2012 indicate that CRC is the third most frequent. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
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related death in the region (in both sexes combined) with an
estimated 80,000 new cancer cases and almost 44,000 cancer
deaths; and the burden of CRC is expected to increase by almost
80% by the year 2030, with 140,000 new cases and 80,000 cancer
deaths due to demographic changes [1]. The methods used to make
these estimations rely on the best available data and depend
largely on high-quality cancer incidence and mortality data, which
for most countries in the CSA region are still lacking; however, the
expected increases in the number of CRC cases in future years are
alarming.
We describe the current incidence and mortality patterns from
CRC in Central and South America and present an overview of these
countries' capacity for screening in order to describe their efforts to
address this increasing CRC burden.
2. Methods
The present analysis includes colon (C18–C19) and rectum
(C20) cancers combined (C18–20), as coded by the 10th edition of
the International Classiﬁcation of Diseases for Oncology (ICD-10).
In spite of their different etiologies, colon and rectum cancers were
combined to avoid possible misclassiﬁcation of tumors diagnosed
at the rectosigmoid junction [3,4]. We also compared the incidence
patterns for colon and rectum cancers and they were fairly similar,
hence we considered them as a single entity. The analysis of
mortality data included colon and rectum cancers as well as
tumors of the anal canal (anus) C18–C21 because rectum and anus
cancers (C19–C21) are always reported together in this database
[14]. Anal cancer is a rare disease and represents about 4% of all
lower gastrointestinal malignancies [15,16]. A similar proportion of
anal cancers was diagnosed in the Central and South American
region (4%) and thus are unlikely to change the overall mortality of
CRC. For simplicity, we refer to these cancers collectively as
colorectal cancers (CRCs).
The data sources and methods are described in detail in an
earlier article in this issue. In brief, from the 22 countries located in
Central and South America (including Cuba), we obtained regional
and national-level incidence data from 48 population-based
cancer registries in 13 countries and cancer deaths from the
World Health Organization mortality database for 18 countries. We
estimated age-standardized incidence (ASR) and mortality (ASMR)
rates per 100,000 person-years using the direct method and the
World standard population [17,18]. We estimated national ASRs by
aggregating the data from the available cancer registries using a
weighted average of local rates. To describe incidence and
mortality time trends, we calculated the estimated annual percent
change (EAPC) using the method proposed by Esteve et al. [19].
Registries that provided formal consent to use data by individual
year of diagnosis for 10-years were included in the time-trend
analysis. Trends in incidence and mortality and EAPCs were
estimated for four countries (Table 1). All of the EAPCs were tested
for equality to zero by using the corresponding standard errors. We
considered EAPCs statistically signiﬁcant if the P-value  0.05. We
conducted the data analysis in Stata version 12.1 (StataCorp) [20].Table 1
Countries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry Information on the country's capacity for CRC screening was
obtained from the WHO 2013 non-communicable diseases country
capacity survey [21] and complemented with information from the
Latin American expert summit for metastatic CRC [22] and from
the Ministry of Health for the pertinent countries.
3. Results
3.1. Incidence and mortality rates
CRC was among the ﬁve most common cancers diagnosed in
males and females (except in El Salvador, where it ranked seventh
and ninth, respectively) and one of the eight most frequent causes
of cancer deaths in the Central and South American region
(Table 2). Males had higher CRC incidence and mortality rates than
females (male-to-female ratios between 1 and 1.5:1 and 1–1.8:1,
respectively), except in Cuba, Ecuador and French Guyana (male-
to-female ratio 0.9:1).
During the most recent period evaluated (i.e., 2003–2007), the
incidence of CRC for most countries was between 10.3 and 16.8 for
males and females. The highest incidence rates for males and
females were observed in Uruguay (34.2 and 24.7, respectively),
Brazil (27.7 and 21.5) and in males in Argentina (25.2), whereas the
lowest rates were in El Salvador (1.5 and 1.3). Overall, mortality
rates were below 10 for both males and females, except in Uruguay
(17.7 for males and 12.0 for females), Cuba (10.0 for males and
11.3 for females) and males in Argentina (14.6).
3.2. Time trends
In the four countries evaluated, the incidence of CRC increased
steadily in Brazil (1997–2007), Chile (1997–2008), and Costa Rica
(1985–2007) in both sexes since the mid-1990s or early 2000s
(Fig. 1). In the most recent 10-year period, the largest increase in
incidence of CRC was observed in Chilean (EAPC = 4.1, P < 0.05) and
Costa Rican (EAPC 3.1, P > 0.05) males and Argentinean females
(EAPC = 3.6, P > 0.05) (Fig. 2).
The highest increase in mortality was observed in Costa Rican
males and Brazilian males and females, with average increases of
about 2% per year (P > 0.05) (Figs. 1 and 2).
3.3. Countries' capacity for CRC screening
Effective screening programs can reduce CRC incidence by
detection and removal of precursor lesions (adenomatous polyps)
and can reduce mortality by early detection of localized disease
(conﬁned to the mucosa) if accompanied by effective diagnostic
follow-up procedures and treatment [23–25]. CRC screening with
fecal occult blood tests (FOBTs) is associated with a 16% decrease in
CRC mortality [24,25].
According to the ofﬁcial country response to the WHO
2013 non-communicable diseases country capacity survey [21],
Argentina, Brazil, Costa Rica, Cuba, Ecuador, Guyana, Honduras,
Suriname, Uruguay and Venezuela reported that bowel cancer
screening was generally available, either by digital rectal exam or
by colonoscopy, at the primary healthcare level. Several CentralPeriod % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) from colorectal cancer in Central and South America, all ages.
Country Sex Incidence Mortalitya
Cases Crude Rate ASR (W) MV (%) Rankb M:F Deaths Crude rate ASR (W) Rankb M:F
Central America
Belize (2003–07) M – – – – – 22 3.2 5.6 5 1.8
F – – – – – 14 2.0 3.0 8
Costa Rica (2003–07) M 1319 12.2 14.6 84 3 1.1 281 3.9 5.3 5 1.0
F 1352 12.9 13.6 80 4 308 4.4 5.6 4
Cuba (2004–07)c M 419 25.6 15.4 75 3 1.0 3330 14.7 10.0 4 0.9
F 456 28.3 15.5 65 3 4454 19.9 11.3 3
El Salvador (1999–03)c M 128 1.0 1.3 84 7 0.9 238 1.7 2.2 7 0.9
F 191 1.3 1.5 87 7 328 2.1 2.4 9
Guatemala (2003–07) M – – – – – 464 1.5 2.5 7 1.0
F – – – – – 528 1.6 2.4 7
Mexico (2006–10)c M 1027 6.0 7.4 100 2 1.2 9654 3.5 5.4 6 1.3
F 982 5.6 6.1 100 3 9107 3.1 4.3 8
Nicaragua (2003–07) M – – – – – 274 2.0 3.4 5 1.0
F – – – – – 305 2.2 3.3 5
Panama (2003–07) M – – – – 489 6.0 7.0 4 1.2
F – – – – – 451 5.6 5.9 4
South America
Argentina (2003–07)c M 3169 25.7 25.2 79 3 1.5 16,441 17.4 14.6 4 1.6
F 2798 21.7 16.9 76 3 14,571 14.8 8.9 3
Bolivia (2011)c M 51 3.9 4.2 98 2 1.4 – –
F 43 3.2 3.0 100 4 – –
Brazil (2003–07)c M 11774 21.1 27.7 86 2 1.3 23,928 5.2 6.1 5 1.1
F 13251 21.5 21.5 84 2 27,165 5.8 5.6 4
Chile (2003–07)c M 305 13.0 14.0 82 4 1.1 3425 8.5 8.1 5 1.2
F 319 14.3 12.7 81 4 3987 9.7 6.9 7
Colombia (2003–07)c M 1152 12.7 14.2 89 4 1.1 4835 4.6 6.3 5 1.0
F 1395 13.9 13.0 89 3 5801 5.3 6.0 6
Ecuador (2003–07)c M 379 8.0 9.7 88 4 1.0 954 2.8 3.5 6 0.9
F 482 9.4 9.7 82 5 1138 3.4 3.7 6
French Guyana (2003–08)c M 52 10.5 15.7 94 5 0.9 – – – –
F 62 12.4 16.8 100 3 – – – –
Paraguay (2003–07) M – – – – – 478 3.2 4.6 4 1.1
F – – – – – 484 3.3 4.3 3
Peru (2001–05)c M 916 10.0 10.8 84 4 1.0 1633 2.4 3.3 5 1.0
F 989 10.3 10.3 79 4 1969 2.9 3.4 6
Suriname (2003–07) M – – – – – 59 4.7 6.1 4 1.3
F – – – – – 54 4.3 4.5 4
Uruguay (2003–07) M 2366 49.3 34.2 86 3 1.4 1298 26.9 17.7 3 1.5
F 2389 46.5 24.7 83 2 1370 26.5 12.0 2
Venezuela (2003–07) M – – – – – 2942 4.4 6.0 4 1.1
F – – – – – 3139 4.7 5.5 5
M, males; F, females; ASR, age standardized incidence rate; MV, microscopic veriﬁcation; M:F, male-to-female ratio (female as the referent category).
a Mortality data includes colon, rectum and anus (C18–C21).
b Rank across cancer types, based on highest ASR excluding: all sites but C44 and all sites.
c Incidence rates were estimated using aggregated data from regional cancer registries.
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for early detection (management and follow-up) of CRC; however,
screening programs in the region are uncommon [24,26].
Countries which have implemented screening programs are
Uruguay and Argentina. Uruguay has had a National Policy for CRC
detection (Programa de Cáncer Colo-Rectal) since 1998 whichincludes annual screening for asymptomatic individuals aged
50–70 by immunochemical FOBT (iFOBT) with follow-up of
positive cases by colonoscopy [27]. A feasibility study conducted
in CRC screening using iFOBT among 11,734 individuals older than
50 years showed a very high compliance rate with iFOBT (90.1%)
and good compliance with colonoscopy (75.1%). Nearly 38% of
Fig. 1. Trends in colorectal cancer incidence and mortality, all ages.
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Fig. 2. Estimated annual percentage change in age-standardized incidence and mortality rates (per 100,000) from colorectal cancer.
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underwent colonoscopy examinations: 16% had advanced cancer
and 14% had early cancer, while 40% had high-risk adenoma and
30% had low-risk adenoma [28]. Uruguay has also initiated a study
to promote screening and healthy behaviors in general and in
higher cancer risk populations (14,000 individuals) [29].
Argentina introduced a national policy for CRC prevention and
early detection (Programa Nacional de Prevención y Detección
Temprana del Cáncer Colorrectal) in 2013, which seeks to include the
management and follow-up of CRC among high-risk populations and
to establish a national screening program based on iFOBT [30].
Countries which have initiated pilot studies for CRC screening
programs include Brazil, Chile, Cuba and Ecuador. The Brazilian
Association of Intestinal Cancer Prevention and the Colorectal
Cancer Prevention and Screening Program initiated a screening
program with iFOBT in a university setting including 5000 people
older than 50 years. From August 2006 to March 2007, compliance
with iFOBT was 80%, and with colonoscopy was 86.5%. Of the
participants who underwent colonoscopies: 25% had diverticular
disease, 28% had one or more polyps, and 4% had adenocarcinoma.
In spite of these encouraging results, the authors concluded that
there is insufﬁcient evidence to estimate the actual impact of the
campaign at this early stage [31].
A multicenter studyconducted in Chile of nearly 6400 individuals
older than 50 years screened with iFOBTshowed compliance rates of
77% for iFOBT and 50.1% for colonoscopy. It identiﬁed adenomas and
high-risk adenomas in 26% and 6% of the patients who underwent
colonoscopy examinations, respectively, with a detection rate of
polyps, high-risk adenomas and cancer of 75, 12 and 2 per
1000 screened individuals, respectively [32]. In 2012, Chile began
the National Screening Project aiming to screen 30,000 people
annually over the next 5 years with iFOBTand colonoscopy for those
with positive results or family history of CRC. From June 2012 to July
2014, 10,575 asymptomatic participants 50–75 years old were
screened with iFOBT. Compliance rates for both iFOBT and
colonoscopy were 94% examinations. Of the 1680 colonoscopies
completed, 42% were adenomas, and 6% were cancer [33].
Cuba introduced iFOBT to the 116 municipalities with the
highest CRC burden in 2013; more than 50,000 individuals 50 years
and older were screened, reaching a coverage of 3% and 10%
positive tests [34].
Ecuador began a pilot study for CRC screening in the Pablo
Arturo Suárez hospital since 2012; however, there is limited
information available [35].
Mexico does not currently have a national CRC screening
program, although some initiatives have emerge at the local and
particular healthcare provider levels in some states. However, the
use of screening services is low due to socioeconomic and cultural
differences; thus patients are usually diagnosed at advanced
disease stages [36]. In Mexico City, a colonoscopy screening study
among 99 asymptomatic individuals 40–79 years old – within an
employee-provided wellness program at the Medica Sur Hospital –
showed that 35 patients had CRC (17 of them had adenomas) [37].
This study showed a participation rate of 20% (600 invitations and
123 agreed to participate) which raises questions about the
acceptance of colonoscopy for screening asymptomatic popula-
tions [37].
Awareness campaigns that have been carried out in Bolivia,
Colombia, Costa Rica, Peru and Venezuela have not been entirely
successful in reaching the population, as CRC cases are usually
diagnosed after the disease has metastasized. The perceived
challenges for screening were lack of awareness and misinforma-
tion about CRC among the general public, the media, primary care
providers, and policymakers [22].
Argentina has reported some success in the screening
awareness program in urban areas and it is now being tried inrural areas [22]. Brazil, on a small scale, has seen growing demand
for preventive screening in colonoscopy services by medical
indication or request, indicating awareness of the patients of CRC
[38]. In Mexico, an educational awareness campaign uses a large
inﬂatable colon for people to walk through to visualize a healthy
colon/rectum and polyps; however, it has not had the same success
as the breast cancer campaign [22].
4. Discussion
This study shows that incidence and mortality rates from CRC
vary considerably across countries in the Central and South
American region (8–9-fold and 3–5-fold, respectively), and that
males generally had higher rates than females. Uruguay, Brazil and
Argentina (males) experienced by far the highest incidence of CRC
for both males and females (25.2–34.4 and 21.5–24.7, respectively)
with rates reaching incidence levels similar to those in countries
with higher levels of human development, such as the United
States (34.4 and 25.2) and Canada (41.7 and 27.9) for 2003–
2007 period [39]. Although mortality from CRC is below 10 per
100,000 in most countries, males and females in Uruguay (17.7 and
12.0, respectively) and Cuba (10.0 and 11.3) and males in Argentina
(14.6) carried a higher mortality burden than those in the United
States (12.0 and 8.3, respectively) and Canada (14.6 and 9.2,
respectively) [14].
Similar incidence rates of colon and/or rectal cancer have been
reported in males and females in Uruguay (2002–2006) and in
females in Cuba (2000–2002) [40,41]. In contrast, higher incidence
rates of CRC were described in Colombia (1995–1999 and 1998–
2002), whereas in Costa Rica (1998–2002) rates were slightly
lower for both males and females [3,42]. Comparable mortality
rates from CRC have previously been reported in several Central
and South American countries [4,43–45]; slightly lower mortality
rates have been reported in Mexico (2005–2007) and Colombia
(1995–1999) [42,46]. These might be explained by the differences
in the periods evaluated, changes in registration practices, changes
in CRC rates over time, as well as changes in the prevalence of risk
factors related to this disease [10,43,46,47].
In Chilean males, the incidence of CRC increased on average 4.1%
per year over the last 10-year period. In Argentina, Brazil, Chile
(females) and Costa Rica incidence increased on average 2–3.6%
per year in both males and females; however, trend analysis
revealed a change that was not statistically signiﬁcant. These
results seem consistent with the increase in CRC described in
countries which have transitioned towards higher levels of human
development [11,12]. Similarly, increases in incidence of CRC in
both males and females have been described in Cali, Colombia,
from the period 1962–2007 (EAPCs: 2.6% and 2.2%, respectively)
and in Costa Rica (1.7% and 1.3%, respectively) between 1983 and
1987 and 1998–2002 [3,10]. Mortality rates also had an increased
tendency over the last 10-year period in Costa Rican males and
Brazilian males and females (about 2% per year), whereas in
Argentina and Chile mortality rates were rather sTable Several
conﬂicting patterns have been described within the Central and
South American region over the last two decades: (1) increases in
both males and females in Brazil, Chile and Mexico [46,48–52]; (2)
increases in males but not females in Costa Rica, Ecuador and
Venezuela [10,45]; (3) decreases in females but not males in
Argentina [43]; (4) decreases in both males and females in
Argentina, Chile, Mexico and Uruguay [45]; or (5) stable mortality
in both males and females in Cuba [53]. Within-country
discrepancies in mortality patterns may be explained by differ-
ences in health infrastructure, treatment and healthcare access,
and higher diagnostic costs [24,25], as well as changes in
certiﬁcation and coding and differences in the cancer site groups
M.S. Sierra, D. Forman / Cancer Epidemiology 44S (2016) S74–S81 S79included (i.e., colon, rectum, bowel cancer) and periods evaluated
[6,46–48].
Factors that may also explain the geographic variation in CRC
rates include differences in the prevalence of obesity [54,55],
physical inactivity [56,57], smoking and heavy alcohol consump-
tion [13], diets high in meat (red and processed) consumption and
low in vegetables and fruit consumption [58–64]. Driven by
economic growth, the Central and South American region has
undergone a signiﬁcant nutritional transition over the last few
decades, and the prevalence of overweight and obesity has
concomitantly been increasing due to the increased consumption
of energy-dense foods which are high in sugars and saturated fats
together with increased physical inactivity levels [65–67].
It is possible that the observed increase in CRC rates since the
mid-1990s in Argentina, Brazil, Chile and Costa Rica may reﬂect a
tendency towards the adoption of a more westernized lifestyle and
changes in dietary habits [46,47]. This could also explain the
elevated CRC rates observed in Uruguay, Brazil, and Argentina,
characterized by a high consumption of beef and processed meat
[68], which contrast with the low mortality rates of CRC observed
in El Salvador, Guatemala, Belize, Nicaragua, Peru, Ecuador, Mexico,
Paraguay, and Suriname (<5.0). For example, Mexico seems to have
a favorable pattern for CRC with diets reportedly poor in red and
processed meat and instead includes home-made foods with beans
and includes legumes, corn products, cereals, and tomatoes [46]. In
contrast, Uruguay [69,70] and Argentina [71] have some diets
characterized by high consumption of red meat and processed
meats and fat/oils (“Western” or “Southern Cone” patterns) which
increased the risk of CRC in case–control studies. However, there is
a need for further studies to better understand the underlying
mechanisms between dietary patterns and CRC risk.
Recent estimations indicate that 15% of the colon and 8% of the
rectum cancers estimated to occur in Latin American (including
Caribbean) men in 2012 were attributable to overweight and
obesity (body mass index (BMI) 25 versus <25 kg/m2), and
approximately 9% of the colon and 5% of the rectum cancers that
occurred in women were due to BMI  25 [54]. By the year 2030,
approximately 50% of men and 60% of women in the region are
estimated to be overweight or obese, and in Cuba and Panama
these ﬁgures are more alarming as about 90% of the population are
estimated to fall into the overweight or obese categories [67];
these expected increases in BMI would probably lead to a higher
proportion of CRC cases attributable to obesity by 2030.
Smoking and alcohol patterns may also explain the geographic
variation and sex disparity in CRC trends. Cuba, for example, had
the highest incidence and mortality of CRC in Central America, and
also had one of the highest prevalences of smoking (43% in men
and 27% in women in 2005) [72] and per capita alcohol
consumption (13.9 L in men and 6.6 L in women, of pure alcohol
per year in 2003–2005) in the Central and South American region
[73]. Ecuador, Guatemala and Costa Rica had the lowest smoking
prevalence (2.5–8% in men and 3–5% in women in 2005) and
Colombia, Costa Rica (men), and Bolivia and Peru (women) had the
lowest per capita alcohol consumption in the region (11–12.6 L in
men and 4.4–5.6 L in women per year in 2003–2005) [73]. The
smaller increase in incidence of CRC observed in females as
compared to males in Chile, Argentina, Brazil and Costa Rica may
reﬂect the slower adoption of smoking [74]. There is, however, a
lack of historical data on smoking to further explore this possible
association. Moreover, the combined effect of smoking, alcohol
consumption and obesity may have contributed to the observed
geographic variation in CRC. Hence, a better understanding of these
relationships, including dietary patterns, may provide relevant
information in the etiology of this disease.
Other established factors known to increase the risk of CRC –
such as a family history of CRC [75] and inﬂammatory boweldisease [76] – are unlikely to explain the variation in CRC in the
region because they account for less than 1% of the CRC cases
diagnosed in the general population. Known protective factors for
CRC – such as regular use of aspirin and other non-steroidal anti-
inﬂammatory drugs (NSAIDs) [77–80], oral contraceptives (OCs)
and estrogen-only menopausal therapy [81,82] – are thought to
have played a role in reducing CRC rates. The increased use of OCs
and estrogen-only menopausal therapy decades ago perhaps led to
the differences in CRC observed between males and females in a
Canadian study [83]. Whether changing patterns in oral contra-
ception and menopausal therapy and aspirin use have inﬂuenced
the current rates across the Central and South American region is
yet to be investigated. Overall, the short- and long-term impacts of
changes in risk factors, screening and treatment on CRC trends
represents a complex set of relationships [7].
It is possible that the elevated incidence rates in Uruguay may
be a reﬂection of screening activities; however, there is a lack of
long-term incidence data to evaluate whether rates have been
increasing after 1998 (the implementation of screening [27]).
Given the recent plans for CRC screening in Argentina [30], it is
expected that the incidence of CRC will increase in the near future
due to the detection of previously undiagnosed disease. Establish-
ing optimal CRC screening programs across countries in the Central
and South American region is challenging because of lack of
healthcare access and coverage, inadequate funding, regional
differences, and lack of personnel and structural deﬁciencies, and
therefore may not be feasible [22,24,26,36,38]. This is particularly
true in countries such as Belize, Bolivia, El Salvador, Guatemala,
Nicaragua, Panama, Paraguay, and Peru, where CRC screening is not
generally available at the primary healthcare level [21] and access
to improved CRC treatment is perhaps a higher priority than
screening [26].
We presented a comprehensive analysis on the current burden
of CRC in Central and South America by describing incidence data
from 13 countries (48 cancer registries), more than the data
published in the latest volume of Cancer Incidence in Five
Continents (eight countries, 22 cancer registries) [39] and
mortality data from 18 countries. However, data patterns should
be interpreted with caution because the data are limited by
geographical coverage, with the exception of the national cancer
registries of Costa Rica and Uruguay. Hence, countrywide incidence
rates are represented by aggregated data from regional cancer
registries which do not cover the entire country. Given the current
status of CRC in the region and the countries' continued transition
towards higher levels of human development, it is imperative to
continue monitoring CRC incidence and mortality as the data
generated by population-based cancer registries is crucial for
cancer control planning.
5. Conclusion
Colorectal cancer is one the ﬁve the leading cancer diagnoses in
Central and South America in both sexes. The geographic variations
and sex gap in CRC rates observed are probably due to differences
in the prevalence of obesity, physical inactivity, diet, smoking and
high alcohol consumption, as well as early detection and cancer
registration practices. The highest rates seen in Uruguay, Brazil and
Argentina are reaching incidence levels similar to those in
countries with higher levels of human development. The rapid
increases in the incidence of CRC observed among males in Chile
seem consistent with the increase in CRC described in countries
that are transitioning towards higher levels of human develop-
ment.
In response to the increasing burden of CRC in the region, most
countries have developed national CRC screening guidelines, and
Uruguay and Argentina have implemented national screening
S80 M.S. Sierra, D. Forman / Cancer Epidemiology 44S (2016) S74–S81programs. Challenges to establishing optimal CRC screening
programs in Central and South American countries include lack
of healthcare access and coverage, inadequate funding, regional
differences, and lack of trained personnel and infrastructure;
establishing such programs therefore may not be feasible.
Given the current status of CRC in the region, the limited
capacity for screening, and the countries' continued transition
towards higher levels of human development, it is imperative to
continue monitoring CRC incidence and mortality, as the data
generated by population-based cancer registries are crucial for
cancer control planning.
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